CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Everyone at CCTG would like to congratulate Dr Frances Shepherd who was recently awarded the Lifetime Contribution Prize from the Canadian Cancer Society. She is an international leader in clinical and translational lung cancer research whose work has transformed the standard of care for patients in Canada and around the world.
Researchers are leveraging new technology to identify tiny amounts of cancer cell DNA in the blood (circulating tumour DNA – ctDNA) as an indicator of the presence of otherwise undetectable numbers of residual colon cancer cells after surgical removal of the main tumour.
CCTG is still accepting members for our Equity, Diversity, Inclusivity, Indigenization, Accessibility (EDIIA) Working Groups as we strive to create a more equitable, diverse, inclusive, accessible, and culturally safe community for our network and for our patient participants.
The CCTG HD12 trial is the second study in the RADAR international trial and has recently opened in Canada. Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.
